Calamos Advisors LLC Acquires 45,747 Shares of Stryker Corporation $SYK

Calamos Advisors LLC raised its stake in Stryker Corporation (NYSE:SYK) by 40.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 158,628 shares of the medical technology company’s stock after buying an additional 45,747 shares during the period. Calamos Advisors LLC’s holdings in Stryker were worth $52,124,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. AMG National Trust Bank lifted its stake in Stryker by 18.9% in the first quarter. AMG National Trust Bank now owns 18,422 shares of the medical technology company’s stock worth $6,053,000 after acquiring an additional 2,927 shares during the period. Mattern Capital Management LLC grew its holdings in Stryker by 0.8% in the first quarter. Mattern Capital Management LLC now owns 26,650 shares of the medical technology company’s stock worth $8,757,000 after purchasing an additional 211 shares during the last quarter. Legacy Capital Group California Inc. grew its stake in Stryker by 81.0% during the 1st quarter. Legacy Capital Group California Inc. now owns 2,709 shares of the medical technology company’s stock worth $890,000 after buying an additional 1,212 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in shares of Stryker by 24.8% during the first quarter. Bleakley Financial Group LLC now owns 22,438 shares of the medical technology company’s stock valued at $7,373,000 after acquiring an additional 4,465 shares in the last quarter. Finally, Center for Financial Planning Inc. increased its stake in Stryker by 2.6% during the 1st quarter. Center for Financial Planning Inc. now owns 5,070 shares of the medical technology company’s stock valued at $1,666,000 after purchasing an additional 127 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SYK shares. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. cut their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a report on Friday, May 1st. UBS Group reduced their target price on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Truist Financial restated a “hold” rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, Robert W. Baird set a $385.00 price objective on Stryker in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Stryker Trading Up 0.7%

Shares of Stryker stock opened at $332.20 on Tuesday. The stock has a 50 day moving average of $310.47 and a 200 day moving average of $337.68. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a market capitalization of $127.35 billion, a price-to-earnings ratio of 38.45, a PEG ratio of 2.11 and a beta of 0.77. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.